NewEdge Advisors’s Vaxcyte PCVX Stock Holding History

NewEdge Advisors’s Portfolio PCVX Stock Details PCVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-15	Closed	-$872	–	4332
2026 Q1	$872	Buy	+15	New	+$814	﹤0.01%	3922
2025 Q3	–	Sell	-14	Closed	-$455	–	4215
2025 Q2	$455	Sell	14 -15	-52%	-$492	﹤0.01%	3810
2025 Q1	$1.09K	Hold	29	–	–	﹤0.01%	3606
2024 Q4	$2.37K	Hold	29	–	–	﹤0.01%	3414
2024 Q3	$3.31K	Hold	29	–	–	﹤0.01%	3283
2024 Q2	$2.19K	Hold	29	–	–	﹤0.01%	3319
2024 Q1	$1.98K	Hold	29	–	–	﹤0.01%	3370
2023 Q4	$1.82K	Buy	+29	New	+$1.51K	﹤0.01%	3352

Other funds holding PCVX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

PBPIA

Pivotal bioVenture Partners Investment Advisor San Francisco, California $308M AUM 120.89% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

NewEdge Advisors's PCVX Position: Q2 2026 in Review

NewEdge Advisors sold out of Vaxcyte (PCVX) in Q2 2026, closing a stake of 15 shares — an estimated $872 sold.

NewEdge Advisors first reported a position in PCVX in Q4 2023 and held it in 8 quarters. The position peaked at $3.31K in Q3 2024. 222 funds tracked by Wall St. Rank hold PCVX as of Q2 2026.

NewEdge Advisors reported no remaining Vaxcyte position as of Q2 2026 after selling out during the quarter.
NewEdge Advisors sold 15 Vaxcyte shares in Q2 2026, an estimated $872.
NewEdge Advisors first reported a position in Vaxcyte in Q4 2023 and held it in 8 quarters.
NewEdge Advisors's Vaxcyte position peaked at $3.31K in Q3 2024.
222 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2026.

Based on NewEdge Advisors's 13F filing for Q2 2026, filed 12 Aug 2026.